. 2021 Aug 1;47(6):1150–1159. doi: 10.1590/S1677-5538.IBJU.2021.0161

Table 2. Comparison of treatment groups in assessment variables.

		Group 1 n=29	Group 2 n=29	Mann-Whitney-U test
Severity of incontinence - 24-h Pad test (gr), (mean±SD)
Pretreatment		42.06±22.15	41.48±26.25	0.779
8^th week		26.65±20.69 ^*	7.05±11.97 ^*	0.001
PFM strength - Perineometer (cmH2O), mean±SD
	Pretreatment	23.96±9.75	23.55±11.69	0.888
	8^th week	24.48±9.62	28.13±13.33 ^*	0.308
Bladder diary
a. Frequency, mean±SD
	Pretreatment	10.44±2.75	11.75±3.69	0.082
	8^th week	8.79±2.27 ^*	6.51±1.95 ^*	<0.001
b. Nocturia, mean±SD
	Pretreatment	2.77±0.62	2.55±2.09	0.542
	8^th week	1.86±0.58 ^*	0.89±0.90 ^*	<0.001
c. Incontinence episodes, mean±SD
	Pretreatment	4.00±1.82	3.82±2.76	0.178
	8^th week	2.68±1.83 ^*	0.68±1.10 ^*	<0.001
d. Number of pads, mean±SD
	Pretreatment	3.55±2.38	3.31±2.17	0.602
	8^th week	2.51±1.80 ^*	1.58±1.63 ^*	0.017
Symptom severity - OAB-V8, mean±SD
	Pretreatment	25.37±6.48	25.93±5.28	0.749
	8^th week	14.44±5.05 ^*	8.89±5.56 ^*	<0.001
Quality of life - IIQ7, mean±SD
	Pretreatment	12.79±6.76	13.72±5.84	0.714
	8^th week	11.17±6.68 ^*	6.27±6.19 ^*	0.003
Treatment satisfaction (1-5), mean±SD
	8^th week	2.97±0.38	4.41±0.73	<0.001

Group1, Bladder Training; Group2, Bladder Training + Intravaginal Electrical Stimulation; OAB-V8, Overactive Bladder Questionnaire; IIQ-7, Incontinence Impact Questionnaire; PFM, Pelvic floor muscle;

P<0.05: Wilcoxon test comparison with baseline values